Results 51 to 60 of about 25,112 (170)

Retrospective Analysis of Blood Donor Deferral Reasons and Optimization Suggestions for Deferral Policies

iLABMED, EarlyView.
This retrospective study analyzes the deferral reasons for 148,282 blood donors during 2019–2023 (overall deferral rate: 12.37%), identifying primary deferral reasons (e.g., elevated ALT for temporary deferral at 51.33%, HBsAg positivity for permanent deferral at 4.12%).
Limei Feng, Li Liu, Rui Wang, Ting Zhang, Wei Guo, Yang Yu   +5 more
wiley   +1 more source

Prevalence of HBV, HDV and retrovirus infection in the matsés ethnic group in Loreto, Peru

Revista Peruana de Medicina Experimental y Salud Pública, 2020
Observational, cross-sectional, populational study to determine the prevalence of infection by hepatitis B virus (HBV), hepatitis D virus (HDV), human immunodeficiency virus (HIV) and human T-lymphotropic virus type 1 and 2 (HTLV-1/2) in the Matsés ...
César Cabezas, Omar Trujillo, Johanna Balbuena, Luis Marin, Magna Suárez, Max Themme, Hugo Rodriguez, Pedro Valencia, Luis Crispin-Huamani   +8 more
doaj   +1 more source

Human Milk Practices in Swedish Neonatal Units: Results From a Nationwide Survey

Acta Paediatrica, EarlyView.
ABSTRACT Aim The aim of this study was to describe the routines for handling mother's own milk and donor human milk in Swedish neonatal care units related to national guidelines. Methods A web‐based survey of 24 of 38 neonatal units and 19 of 28 human milk banks in Sweden. Results Despite national guidelines, breast milk handling varied widely.
Ylva Thernström Blomqvist, Anna‐My Lund, Fredrik Ahlsson, Jenny Ericson, Charlotta Karlsson, Josefin Lundström, Ingela Sandström, Anna Gustafsson   +7 more
wiley   +1 more source

Evaluation of human T-lymphotropic virus prevalence/co-infection rates for a four-year period in a non-metropolitan blood center in Southeast Brazil

Revista da Sociedade Brasileira de Medicina Tropical, 2016
: INTRODUCTION: Human T-lymphotropic virus types 1/2 (HTLV-1/2) are distributed worldwide and are endemic in specific regions. METHODS: Serological evaluation of the HTLV-1/2 prevalence and co-infection rate [human immunodeficiency virus (HIV ...
Mariana Tomazini Pinto, Svetoslav Nanev Slavov, Vanderléia Bárbaro Valente, Eugênia Maria Amorim Ubiali, Dimas Tadeu Covas, Simone Kashima   +5 more
doaj   +1 more source

Perceptions of donor screening—Do I always need to tell the truth?

Transfusion Medicine, EarlyView.
Abstract Background The Donor Health Assessment Questionnaire (DHQ) is fundamental to blood safety. We describe attitudes towards truthfulness among first‐time donors who tested positive for transfusion transmissible infections and those who did not.
Sheila F. O'Brien, Lori Osmond, Mindy Goldman   +2 more
wiley   +1 more source

Pathogen‐reduced platelet concentrates in France: Impact on the risk of transfusion‐transmitted infections, 2017–2024

Vox Sanguinis, EarlyView.
Abstract Background and Objectives Pathogen reduction (PR) using amotosalen‐UVA was implemented for 100% of platelet concentrates (PCs) in France in November 2017. No bacterial testing was in place earlier. The impact of PR on the risk of transfusion‐transmitted infections (TTIs) from November 2017 to December 2022 (vs.
Syria Laperche, Virginie de la Taille, Pierre Gallian, Elodie Pouchol, Catherine Humbrecht, Alexandre Montembault, Lucile Malard, Caroline Bacquet, Marianne Asso‐Bonnet, Sophie Le Cam, Thierry Peyrard, Pierre Tiberghien   +11 more
wiley   +1 more source

Re‐entry of donors deferred for false‐reactive screening tests in Canada: 10 years post implementation

Vox Sanguinis, EarlyView.
Abstract Background and Objectives Canadian Blood Services implemented a re‐entry programme in 2014. Donors deferred because of false‐reactive or indeterminate screening tests can provide a specimen for re‐entry testing 6 months after their initial test, and resume donating if they test negative for all infectious markers.
Chinchin Wang, Steven J. Drews, Mark Bigham, Mindy Goldman, Sheila F. O'Brien   +4 more
wiley   +1 more source

Hepatitis C virus/human T lymphotropic virus 1/2 co-infection: Regional burden and virological outcomes in people who inject drugs

World Journal of Virology, 2016
This review analyses current data concerning co-infection with hepatitis C virus (HCV) and human T lymphotropic virus (HTLV)-1/2 in people who inject drugs (PWID), with a particular focus on disease burden and global implications for virological outcome. In addition, the available treatment options for HTLV-1/2 are summarized and the ongoing and likely
Erika, Castro, Elena, Roger
openaire   +4 more sources

Infection with human T-lymphotropic virus types-1 and -2 (HTLV-1 and -2): Implications for blood transfusion safety [PDF]

Transfusion Clinique et Biologique, 2016
Many countries currently perform antibody screening for HTLV-1 infection in blood donors, and this intervention is likely cost-effective in preventing HTLV-1 related diseases in high prevalence countries. However, a number of high-income countries with low prevalence of HTLV-1 infection also perform universal HTLV-1 screening and debate has arisen ...
openaire   +4 more sources

High Frequencies of Functionally Competent Circulating Tax-Specific CD8+ T Cells in Human T Lymphotropic Virus Type 2 Infection [PDF]

The Journal of Immunology, 2009
Abstract Human T lymphotropic virus type 2 (HTLV-2) is characterized by a clinically asymptomatic persistent infection in the vast majority of infected individuals. In this study, we have characterized for the first time ex vivo specific CTL responses against the HTLV-2 Tax protein. We could detect CTL responses only against a single HLA-
André L A, Oliveira, Hitoshi, Hayakawa, Doris, Schor, Ana Claudia C B, Leite, Otávio M, Espíndola, Allison, Waters, Jonathan, Dean, Derek G, Doherty, Abelardo Q-C, Araújo, William W, Hall   +9 more
openaire   +2 more sources